腹水:MELD评分未涵盖的普外科手术风险标志
基于2005-2014年NSQIP数据库30391例疝修补、粘连松解和胆囊切除术患者,分层分析显示腹水在各MELD评分层均独立增加并发症和死亡风险,提示MELD评分可能低估腹水患者的手术风险,纳入腹水的预测模型或更准确。
要点
- 腹水在低、中、高MELD评分层均增加并发症风险,校正后OR分别为3.22、3.70、6.38。
- 腹水对死亡风险的增加更显著,低、中、高MELD层OR分别为9.40、15.24、28.56。
- MELD评分可能低估腹水患者的围术期风险,评估时应将腹水纳入考量。
核心结论
- 腹水在多种普外科手术中增加并发症和死亡风险,且该风险未被MELD评分充分反映。
研究设计与样本
- 回顾性队列研究,数据来自美国国家手术质量改进计划(NSQIP)数据库2005-2014年。
- 纳入接受疝修补、粘连松解和胆囊切除术的患者,共30391例。
- 采用单因素分析和逻辑回归,按MELD评分分层和腹水存在与否进行分析。
主要发现
- 与低MELD评分无腹水患者相比,低MELD评分伴腹水者并发症OR为3.22(95%CI 2.00-5.18)。
- 中MELD评分伴腹水者并发症OR为3.70(95%CI 2.64-5.19),高MELD评分伴腹水者OR为6.38(95%CI 4.39-9.26)。
- 死亡风险:低MELD评分伴腹水OR为9.40(95%CI 3.53-25.01),中MELD评分伴腹水OR为15.24(95%CI 8.17-28.45),高MELD评分伴腹水OR为28.56(95%CI 15.43-52.88)。
临床怎么用
- 对拟行疝修补、粘连松解或胆囊切除术的患者,术前应评估是否存在腹水。
- 腹水患者即使MELD评分较低,也应视为高围术期风险,加强术前优化和术后监护。
- 考虑使用纳入腹水的预测模型以更准确评估手术风险。
局限性
- 回顾性数据库研究,可能存在未测量的混杂因素。
- 仅纳入疝修补、粘连松解和胆囊切除术,结论外推至其他普外科手术需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ascites and the Model for End-Stage Liver Disease score have both been shown to independently correlate with surgical morbidity and mortality. We evaluated if incorporating the presence of ascites changed postoperative risk as assessed by the Model for End-Stage Liver Disease score. METHODS: Data originated from the National Surgical Quality Improvement Program database from 2005-2014. Patients undergoing hernia repair, adhesiolysis, and cholecystectomy were included. Univariate analysis and logistic regression stratified by Model for End-Stage Liver Disease score and presence of ascites was performed. RESULTS: A total of 30,391 patients were analyzed. When compared to low Model for End-Stage Liver Disease stratum without ascites, the presence of ascites predicted increased risk for complications (low Model for End-Stage Liver Disease with ascites odds ratio 3.22, 95% confidence interval [2.00-5.18], moderate Model for End-Stage Liver Disease with ascites odds ratio 3.70, 95% confidence interval [2.64-5.19], high Model for End-Stage Liver Disease with ascites odds ratio 6.38, 95% confidence interval [4.39-9.26]). These findings hold true for mortality as well (low Model for End-Stage Liver Disease with ascites odds ratio 9.40 95% confidence interval [3.53-25.01], moderate Model for End-Stage Liver Disease with ascites odds ratio 15.24 95% confidence interval [8.17-28.45], high Model for End-Stage Liver Disease with ascites odds ratio 28.56 95% confidence interval [15.43-52.88]). CONCLUSIONS: Ascites increased the risk of morbidity and mortality across multiple general surgery operations. Model for End-Stage Liver Disease may underestimate surgical risk in patients with ascites. Predictive models inclusive of ascites may more accurately predict the perioperative risk of these complex patients.
引用
- Fleming MM, DeWane MP, Luo J, et al. Ascites: A marker for increased surgical risk unaccounted for by the model for end-stage liver disease (MELD) score for general surgical procedures. Surgery. 2018. PMID: 29705097. doi:10.1016/j.surg.2018.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。